

Ventilator Associated Pneumonia (VAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/V267235BA346EN.html>

Date: March 2022

Pages: 109

Price: US\$ 2,000.00 (Single User License)

ID: V267235BA346EN

Abstracts

Ventilator Associated Pneumonia (VAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide

covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 4, 10, 11, 7 and 2 respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Ventilator Associated Pneumonia (VAP) - Overview

Ventilator Associated Pneumonia (VAP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development

Allegra Therapeutics GmbH

Antabio SAS

Aridis Pharmaceuticals Inc

Bioversys AG

Cellular Biomedicine Group Inc

ContraFect Corp

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Entasis Therapeutics Holdings Inc

GangaGen Biotechnologies Pvt Ltd

Helperby Therapeutics Group Ltd

Hoth Therapeutics Inc

Hypo-Stream Ltd

La Jolla Pharmaceutical Company

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Nabriva Therapeutics Plc

Nosopharm SAS

Omnix Medical Ltd

Peptineo

Pfizer Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Pulmobiotics SL

Qilu Pharmaceutical Co Ltd

Revagenix Inc

Shionogi & Co Ltd

Spero Therapeutics Inc

Spexis AG

TGV-Inhalonix Inc

VenatoRx Pharmaceuticals Inc

Wockhardt Ltd

Ventilator Associated Pneumonia (VAP) - Drug Profiles

(AAI-101 + cefepime) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(avibactam + aztreonam) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(avibactam sodium + ceftazidime) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(cefepime + taniborbactam hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(cefepime + zidebactam) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(cilastatin sodium + imipenem + relebactam) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(durlobactam sodium + sulbactam) - Drug Profile

Product Description

Mechanism Of Action

History of Events

AlloJoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

AR-401 - Drug Profile

Product Description

Mechanism Of Action

History of Events

arbakacin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic for Ventilator Associated Pneumonia - Drug Profile

Product Description

Mechanism Of Action

cefiderocol sulfate tosylate - Drug Profile

Product Description

Mechanism Of Action

History of Events

CF-370 - Drug Profile

Product Description

Mechanism Of Action

History of Events

EBX-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

eravacycline dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

FL-058 - Drug Profile

Product Description

Mechanism Of Action

History of Events
fosfomicin disodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
HT-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HY-010B3 - Drug Profile
Product Description
Mechanism Of Action
HY-011B4 - Drug Profile
Product Description
Mechanism Of Action
HY-012B5 - Drug Profile
Product Description
Mechanism Of Action
HY-015B12 - Drug Profile
Product Description
Mechanism Of Action
Iefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
MEMANT-3310 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
nacubactam - Drug Profile
Product Description
Mechanism Of Action
History of Events
NOSO-2G - Drug Profile
Product Description

Mechanism Of Action

History of Events

OMN-6 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Panaecin - Drug Profile

Product Description

Mechanism Of Action

History of Events

panobacumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

PP-1231 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Qn-2251 - Drug Profile

Product Description

Mechanism Of Action

rifabutin - Drug Profile

Product Description

Mechanism Of Action

History of Events

SASPjectPT-3.9 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Hospital Acquired Pneumonia (HAP) and Ventilator Associated
Pneumonia (VAP) - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

SPR-206 - Drug Profile

Product Description

Mechanism Of Action

History of Events

tedizolid phosphate - Drug Profile

Product Description

Mechanism Of Action

History of Events

telavancin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

tosatoxumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

XF-70 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Ventilator Associated Pneumonia (VAP) - Dormant Projects

Ventilator Associated Pneumonia (VAP) - Discontinued Products

Ventilator Associated Pneumonia (VAP) - Product Development Milestones

Featured News & Press Releases

Aug 17, 2021: Venatorx Pharmaceuticals provides update on Cefepime-Taniborbactam

Jun 07, 2021: The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Journal of Pharmacology

Apr 19, 2021: Phico Therapeutics awarded up to \$18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials

Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Recarbrio

Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta

Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta

Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jun 01, 2020: FDA accepts Shionogi's Supplemental New Drug Application with Priority Review for FETROJA (cefiderocol) for the Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO's priority pathogens

May 04, 2020: Aridis recruits Covid-19 patients for AR-301's pneumonia trial

Mar 23, 2020: Cumberland Pharmaceuticals announces initiative to expand availability Of VIBATIV to treat hospital-acquired & ventilator-associated pneumonia resulting from Coronavirus infections

Feb 18, 2020: Aridis Pharmaceuticals to host investor day showcasing APEX technology platform and key opinion leader panel on Pneumonia

Feb 03, 2020: FDA accepts for review supplemental new drug application (sNDA) for RECARBRIO (imipenem, cilastatin, and relebactam) for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)

Nov 11, 2019: Allergan receives FDA Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for ATM-AVI (Aztreonam And Avibactam) for Antibiotic-Resistant Gram-Negative Infections

Oct 15, 2019: New study reveals superiority of Vibativ over Vancomycin in select patients with Bacterial Pneumonia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Ventilator Associated Pneumonia (VAP), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Allecra Therapeutics GmbH, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Antabio SAS, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals Inc, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Bioversys AG, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Cellular Biomedicine Group Inc, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by ContraFect Corp, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Cumberland Pharmaceuticals Inc, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by CytaCoat AB, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Plc, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Entasis Therapeutics Holdings Inc, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Helperby Therapeutics Group Ltd, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Hoth Therapeutics Inc, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Hypo-Stream Ltd, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by La Jolla Pharmaceutical Company, 2022

Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, 2022

Ventilator Associated Pneumonia (VAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics Plc, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Nosopharm SAS, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Omnix Medical Ltd, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Peptineo, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Pfizer Inc, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Pherecydes Pharma SA, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Phico Therapeutics Ltd, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Pulmobiotics SL, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Revagenix Inc, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Spero Therapeutics Inc, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Spexis AG, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by TGV-Inhalonix Inc, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by VenatoRx Pharmaceuticals Inc, 2022
Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, 2022
Ventilator Associated Pneumonia (VAP) - Dormant Projects, 2022
Ventilator Associated Pneumonia (VAP) - Dormant Projects, 2022 (Contd..1)
Ventilator Associated Pneumonia (VAP) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ventilator Associated Pneumonia (VAP), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Ventilator Associated Pneumonia (VAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/V267235BA346EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V267235BA346EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

